July 28, 2021
Article
A recent study of sexually active young women in Africa found that initiation of HIV preexposure prophylaxis (PrEP) was high at 95% and one-fifth showed high adherence at 6 months.
July 23, 2021
Video
The risk of COVID-19 severity in people living with HIV may be less than previously anticipated.
Phase 3 trials for islatravir are underway. What are investigators considering with the Merck investigative drug?
July 22, 2021
Due to limited familiarity with providing antiretroviral medication, many participants were hesitant to initiate PrEP.
Investigators wanted to study usage of F/TAF vs F/TDF in clinical practice and HIV seroconversion.
July 21, 2021
Adherence for daily dosing decreased and event-driven PrEP usage increased in a Chinese study.
In a pilot project, customers were surveyed about HIV risk behaviors to gain further insights and assessed for potential PrEP utilization.
July 20, 2021
New 24-week findings from Merck highlight the potential of a 1-month PrEP option for low-risk patients.
Many respondents reported having a lack of information about the use of PrEP.
More tailored strategies could improve PrEP provision in family planning clinics.
